CompletedPhase 2NCT02612857
Trial of IMO-8400 in Adult Patients With Dermatomyositis
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Idera Pharmaceuticals, Inc.
- Principal Investigator
- Joanna Horobin, MDIdera Pharmaceuticals
- Intervention
- IMO-8400 Dose Group 1(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2015 – 2018
Study locations (20)
- University of Alabama, Birmingham, Alabama, United States
- Phoenix Neurological Associates, Phoenix, Arizona, United States
- University of California, Irvine, Irvine, California, United States
- Stanford Hospital and Clinics, Stanford, California, United States
- George Washington University, Washington D.C., District of Columbia, United States
- University of Miami, Miami, Florida, United States
- Northwestern University, Chicago, Illinois, United States
- University of Kansas, Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University, St Louis, Missouri, United States
- Northwell Health, Great Neck, New York, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02612857 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH